专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009143389A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS 审中-公开
标题翻译：作为激酶抑制剂的磷酸衍生物
公开(公告)号：WO2009143389A1
公开(公告)日：2009-11-26
申请号：PCT/US2009/044918
申请日：2009-05-21
申请人： ARIAD PHARMACEUTICALS, INC. , WANG, Yihan , HUANG, Wei-Sheng , LIU, Shuangying , SHAKESPEARE, William, C. , THOMAS, R., Mathew , QI, Jiwei , LI, Feng , ZHU, Xiaotian , KOHLMANN, Anna , DALGARNO, David, C. , ROMERO, Jan, Antoinette, C. , ZOU, Dong
发明人： WANG, Yihan , HUANG, Wei-Sheng , LIU, Shuangying , SHAKESPEARE, William, C. , THOMAS, R., Mathew , QI, Jiwei , LI, Feng , ZHU, Xiaotian , KOHLMANN, Anna , DALGARNO, David, C. , ROMERO, Jan, Antoinette, C. , ZOU, Dong
IPC分类号： A61K31/505 , A61K31/513
CPC分类号： C07F9/6533 , C07D239/48 , C07F9/587 , C07F9/650941 , C07F9/65122 , C07F9/65127 , C07F9/65216 , C07F9/65217 , C07F9/65218 , C07F9/65583 , C07F9/65586 , C07F9/6561 , C07F9/65616 , C07F9/65685 , C07F9/657172 , C07F9/65846
摘要： The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
摘要翻译：本发明的特征在于其中可变基团如本文所定义的通式（I）的化合物及其制备和用途。

2. 发明申请

WO2010068292A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS 审中-公开
标题翻译：亚胺衍生物作为激酶抑制剂
公开(公告)号：WO2010068292A1
公开(公告)日：2010-06-17
申请号：PCT/US2009/006520
申请日：2009-12-11
申请人： ARIAD PHARMACEUTICALS, INC. , QI, Jiwei , WANG, Yihan , LI, Feng , SHAKESPEARE, William, C. , KOHLMANN, Anna , DALGARNO, David, C. , ZHU, Xiaotian
发明人： QI, Jiwei , WANG, Yihan , LI, Feng , SHAKESPEARE, William, C. , KOHLMANN, Anna , DALGARNO, David, C. , ZHU, Xiaotian
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44 , C07D471/04
摘要： This invention relates to compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
摘要翻译：本发明涉及其中可变基团如本文所定义的通式（I）的化合物及其制备和用途。

3. 发明申请

WO2015195228A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION 审中-公开
标题翻译：用于激酶抑制的异氟醚化合物
公开(公告)号：WO2015195228A1
公开(公告)日：2015-12-23
申请号：PCT/US2015/030576
申请日：2015-05-13
申请人： ARIAD PHARMACEUTICALS, INC. , HUANG, Wei-sheng , GONG, Yongjin , LI, Feng , BENCIVENGA, Nicholas, E. , DALGARNO, David, C. , KOHLMANN, Anna , SHAKESPEARE, William, C. , THOMAS, Ranny, M. , ZHU, Xiaotian , WEST, Angela, V. , YOUNGSAYE, Willmen , ZHANG, Yun , ZHOU, Tianjun
发明人： HUANG, Wei-sheng , GONG, Yongjin , LI, Feng , BENCIVENGA, Nicholas, E. , DALGARNO, David, C. , KOHLMANN, Anna , SHAKESPEARE, William, C. , THOMAS, Ranny, M. , ZHU, Xiaotian , WEST, Angela, V. , YOUNGSAYE, Willmen , ZHANG, Yun , ZHOU, Tianjun
IPC分类号： C07D403/14 , C07D473/16
CPC分类号： C07D471/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/12 , C07D405/14 , C07F9/65583
摘要： Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.
摘要翻译：本文描述了调节激酶活性的化合物和药物组合物，包括突变型EGFR和突变型HER2激酶活性，以及化合物，药物组合物和治疗与激酶活性相关的疾病和病症（包括突变型EGFR和突变型HER2活性）的方法。

4. 发明申请

WO2015175632A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION 审中-公开
标题翻译：用于激酶抑制的杂原子化合物
公开(公告)号：WO2015175632A1
公开(公告)日：2015-11-19
申请号：PCT/US2015/030522
申请日：2015-05-13
申请人： ARIAD PHARMACEUTICALS, INC. , HUANG, Wei-Sheng , LI, Feng , DALGARNO, David, C. , GONG, Yongjin , ISHCHENKO, Alexey, V. , KOHLMANN, Anna , SHAKESPEARE, William, C. , WEST, Angela, V. , XU, Yongjin , YOUNGSAYE, Willmen , ZHANG, Yun , ZHOU, Tianjun , ZHU, Xiaotian
发明人： HUANG, Wei-Sheng , LI, Feng , DALGARNO, David, C. , GONG, Yongjin , ISHCHENKO, Alexey, V. , KOHLMANN, Anna , SHAKESPEARE, William, C. , WEST, Angela, V. , XU, Yongjin , YOUNGSAYE, Willmen , ZHANG, Yun , ZHOU, Tianjun , ZHU, Xiaotian
IPC分类号： C07D403/14 , C07D473/16
CPC分类号： C07F9/6561 , C07D471/06 , C07D487/06 , C07D498/06
摘要： Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.
摘要翻译：调节激酶活性的化合物和药物组合物，包括突变型EGFR和突变型HER2激酶活性，以及化合物，药物组合物和治疗与激酶活性相关的疾病和病症的方法，包括突变型EGFR和突变型HER2 活动，在这里描述。

5. 发明申请

WO2014151761A1 NOVEL CHOLINE KINASE INHIBITORS 审中-公开
标题翻译：新型胆碱激酶抑制剂
公开(公告)号：WO2014151761A1
公开(公告)日：2014-09-25
申请号：PCT/US2014/026404
申请日：2014-03-13
申请人： ARIAD PHARMACEUTICALS, INC. , ZECH, Stephan, G. , KOHLMANN, Anna , LI, Feng , WANG, Yihan , ZHOU, Tianjun , DALGARNO, David, C. , SHAKESPEARE, William, C. , ZHU, Xiaotian
发明人： ZECH, Stephan, G. , KOHLMANN, Anna , LI, Feng , WANG, Yihan , ZHOU, Tianjun , DALGARNO, David, C. , SHAKESPEARE, William, C. , ZHU, Xiaotian
IPC分类号： A61K31/551 , A61P35/00 , C07D403/02
CPC分类号： C07D243/08 , A61K31/551 , C07D245/02 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07F9/645
摘要： This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds.
摘要翻译：本发明涉及通式（I）的化合物：其中可变基团如本文所鉴定，以及化合物的制备和使用。

6. 发明申请

WO2012103279A3 METHODS AND COMPOSITIONS FOR THE SYNTHESIS OF MULTIMERIZING AGENTS 审中-公开
公开(公告)号：WO2012103279A3
公开(公告)日：2012-08-02
申请号：PCT/US2012/022642
申请日：2012-01-26
申请人： ARIAD PHARMACEUTICALS, INCORPORATED , LI, Feng , WANG, Yihan
发明人： LI, Feng , WANG, Yihan
IPC分类号： C07D319/06
摘要： The invention features methods and compositions for the synthesis of multimerizing agents. An exemplary method for producing AP20187 may comprise: (a) coupling 2-N,Ndimethylaminomethyl-1,3-diaminopropane with AP20792 to produce the dimeric alcohol, AP20793; and (b) coupling the AP20793 so produced with API7362 to yield AP20187. In particular embodiments, the method further includes the step of producing API7362 by coupling API7360 with methyl-L-pipecolic acid, or a salt thereof.

7. 发明申请

WO2018112136A1 AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS 审中-公开
公开(公告)号：WO2018112136A1
公开(公告)日：2018-06-21
申请号：PCT/US2017/066291
申请日：2017-12-14
申请人： ARIAD PHARMACEUTICALS, INC.
发明人： BENCIVENGA, Nicholas, E. , DALGARNO, David, C. , GOZGIT, Joseph, M. , HUANG, Wei-Sheng , KOHLMANN, Anna , LI, Feng , QI, Jiwei , SHAKESPEARE, William, C. , THOMAS, Ranny, M. , WANG, Yihan , ZHU, Xiaotian
IPC分类号： C07D417/12 , C07D277/44 , A61K31/427 , A61P35/00
摘要： The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other -threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R 1 , R 2 , R 3 , and n are described herein.

8. 发明申请

WO2018112140A1 BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS 审中-公开
公开(公告)号：WO2018112140A1
公开(公告)日：2018-06-21
申请号：PCT/US2017/066299
申请日：2017-12-14
申请人： ARIAD PHARMACEUTICALS, INC.
发明人： BENCIVENGA, Nicholas, E. , DALGARNO, David, C. , GOZGIT, Joseph, M. , HUANG, Wei-sheng , KOHLMANN, Anna , LI, Feng , QI, Jiwei , SHAKESPEARE, William, C. , THOMAS, Ranny, M. , WANG, Yihan , ZHANG, Yun , ZHU, Xiaotian
IPC分类号： C07D401/14 , C07D235/08 , C07D401/12 , C07D403/04 , A61P35/00 , A61P11/06 , A61K31/4184
摘要： The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R 1 , R 2 , R 3 , and n are described herein.

9. 发明申请

WO2019213115A1 TUNGSTEN PENTACHLORIDE CONDITIONING AND CRYSTALLINE PHASE MANIPULATION 审中-公开
公开(公告)号：WO2019213115A1
公开(公告)日：2019-11-07
申请号：PCT/US2019/029969
申请日：2019-04-30
申请人： L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE , LI, Feng , PLAZA, Sonia , GIRARD, Jean-Marc , BLASCO, Nicolas , LIU, Yumin
发明人： LI, Feng , PLAZA, Sonia , GIRARD, Jean-Marc , BLASCO, Nicolas , LIU, Yumin
IPC分类号： H01L21/02 , H01L21/285 , H01L21/324
摘要： Conditioning of tungsten pentachloride to form specific crystalline phases is disclosed. The specific crystalline phases permit stable vapor pressures over extended periods of time during vapor deposition and etching processes.

10. 发明申请

WO2011081646A1 STEREO-IMAGE QUALITY AND DISPARITY/DEPTH INDICATIONS 审中-公开
标题翻译：立体图像质量和差异/深度指示
公开(公告)号：WO2011081646A1
公开(公告)日：2011-07-07
申请号：PCT/US2010/003151
申请日：2010-12-13
申请人： THOMSON LICENSING , IZZAT, Izzat H. , LI, Feng
发明人： IZZAT, Izzat H. , LI, Feng
IPC分类号： H04N13/00
CPC分类号： G06T7/0022 , G06T7/97 , G06T2207/10021 , H04N13/122 , H04N13/128 , H04N13/144 , H04N13/25 , H04N2213/002
摘要： A variety of implementations are described. At least one implementation modifies one or more images from a stereo-image pair in order to produce a new image pair that has a different disparity map. The new disparity map satisfies a quality condition that the disparity of the original image pair did not. In one particular implementation, a first image and a second image that form a stereo image pair are accessed. A disparity map is generated for a set of features from the first image that are matched to features in the second image. The set of features is less than all features in the first image. A quality measure is determined based on disparity values in the disparity map. The first image is modified, in response to the determined quality measure, such that disparity for the set of features in the first image is also modified.
摘要翻译：描述了各种实施方式。至少一个实施方式从立体图像对修改一个或多个图像，以便产生具有不同视差图的新图像对。新的视差图满足了原始图像对的不一致性的质量条件。在一个具体实现中，访问形成立体图像对的第一图像和第二图像。对于与第二图像中的特征匹配的第一图像的一组特征生成视差图。功能的集合小于第一张图像中的所有功能。基于视差图中的差异值确定质量度量。响应于确定的质量测量，修改第一图像，使得第一图像中的特征集合的视差也被修改。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式